by Truveta staff | Mar 31, 2025 | Research
The overall rate of respiratory virus-associated hospitalizations decreased in February, although influenza continues to be the leading cause of respiratory virus-associated hospitalizations (3.5% of all hospitalizations). Among children aged 0–4 years,...
by Truveta staff | Mar 20, 2025 | Research
Why autoimmune research needs better real-world data Biologics like Humira, Enbrel, and Rinvoq have transformed autoimmune treatment, revolutionizing treatment for patients with chronic inflammatory infections. However, the traditional methods of studying these...
by Truveta staff | Mar 7, 2025 | Research
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in December 2024 were similar to September 2024 (+1.89%). Anti-diabetic medication (ADM) prescribing rates in December 2024 were similar to those in September 2024 (-0.88%). Among ADMs,...
by Truveta staff | Feb 26, 2025 | Research
Heart failure with reduced ejection fraction (HFrEF) remains a leading cause of morbidity and mortality. While guideline-directed medical therapy (GDMT) has been shown to improve left ventricular ejection fraction (LVEF), real-world data on LVEF recovery and GDMT...
by Truveta staff | Feb 20, 2025 | Research
Recently, researchers presented new epilepsy research at the American Epilepsy Society Annual Meeting in Los Angeles, California. Using Truveta Data, the researchers explored two important topics: the link between epilepsy, anti-seizure medications, and cardiac...
by Truveta staff | Feb 19, 2025 | Research
The need for better cardiovascular device insights Medical device companies are at the forefront of innovation, but a lack of real-world clinical data (RWD) hampers progress in studying cardiovascular device performance. Traditional data sources, such as claims and...
